Abstract
Introduction: Breast cancer is the most common cancer among women, accounting for 22% of all female cancers. In breast cancer, the overexpression of human epidermal growth factor receptor-2 (HER-2/neu) is a prognostic marker indicated for stratification of patients for HER-2/neu targeted therapies, while estrogen receptor (ER) and progesterone receptors (PR) are additional prognostic markers in patients with early stage breast cancer and predictive for response to hormonal therapies. Fine needle aspiration cytology (FNAC), can provide enough cellular sample and evaluation of ER, PR and HER2/neu expression patterns has relevant clinical application because the sample can be collected before surgery and help plan management of breast cancer patients. The aim of the study was to evaluate and classify breast cancer by examining HER-2/neu, ER and PR expression patterns using cellblocks.
Methods: A prospective cross-sectional study was carried out using FNAC samples from 30 patients with breast cancer. The ER, PR and HER2/neu protein overexpression patterns were determined by immunocytochemistry. Breast cancer cases were considered positive for ER and PR when 10% or more tumor cells were stained. The HER-2/neu overexpression was assessed on a scale of 0 to 3+ and a score of 3+ was considered positive.
Results: Estrogen receptor positivity was observed in 50% of breast cancer cases, while PR positivity in 47% of the cases and HER2/neu was overexpressed in 13% of breast cancer cases.
Conclusion: Immunocytochemistry performed on cell block is a feasible method for evaluation of ER, PR and HER-2/neu status in breast cancer, especially when the cellblock has adequate tumor cells.
Keywords: Breast cancer, human epidermal growth factor receptor-2, estrogen receptor, progesterone receptor, Immunocytochemistry.
References
- Simpson PT, Reis-Filho, JS, Gale T et al. Molecular evolution of breast cancer. J Pathol 2005; 205: 248-254.
- Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206–2223.
- DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64 :52–62.
- WHO Cervical cancer summary report update. September, 15: 2010.
- Durgapal P, Mathur SR, Kalamuddin M, et al. Assessment of Her-2/neu status using immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology smears: experience from a tertiary care centre in India. Diagn Cytopathol. 2014;42:726–731.
- Bird PA, Hill AG, Houssami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol 2008;15:1983–8.
- Geethamala K, Murthy VS, Vani BR, et al. Comparison of Immunocytochemistry and Immunohistochemistry on Breast Carcinoma: A Boon or a Bane? J Lab Physicians. 2017 Jan-Mar;9(1):5-10.
- Nyagol J, Nyong’o A, Byakika B et al. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer. Anal Quant Cytol Histol 2006; 28:97–103.
- Sayed S, Moloo Z, Wasike R, et al. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Breast 2014; 23:591-6.
- Strasser-Weippl K and Goss PE. Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol 2005; 23: 1751–1759.
- Bueno Angela SP, Viero RM, Soares CT, et al., Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER2 by immunohistochemistry in breast carcinoma. 2013;24:26–32.
- Srivastava P, Kumar B, Joshi U, et al. To Evaluate the Applicability of Parameters of Cytological Grading Systems on Aspirates of Breast J Cytol. 2018 Jan-Mar;35(1):15-21
- Mišković J, Zorić A, Radić Mišković H, et al. Diagnostic Value of Fine Needle Aspiration Cytology for Breast Tumors Acta Clin Croat. 2016 Dec;55(4):625-628
- Nyagol J, Kisato V, Ochuk W et al. Assessment of hormonal receptors and Her2/neu status in breast cancer using cell block: a case study. Afr Cancer 2013; 5: 180-184.
- Gorman BK, Kosarac O, Chakraborty S, et al. Comparison of breast carcinoma prognostic/predictive biomarkers on cell blocks obtained by various methods: Cellient, formalin and thrombin. Acta Cytol. 2012;56:289-96.
- Allred DC, Harvey JM, Berardo M et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11: 155–68.
- Wolff AC, Hammond ME, Hicks DG et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med. 2014; 138: 241–256.
- Kumar SK, Gupta N, Rajwanshi A et al. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma. Cytopathol 2012; 23:181–186.
- Ly M, Antoine M, Dembélé AK, et al. High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology 2012; 83:257-63.
- Schmitt FC, Bento MJ, Amendoeira I. Estimation of estrogen receptor content in fine-needle aspirates from breast cancer using the monoclonal antibody 1D5 and microwave oven processing: correlation with paraffin embedded and frozen sections determinations. Diagn Cytopathol 1995; 13:347–51.
Corresponding Author
Mutinda C. Kyama, Ph.D
Department of Medical Laboratory Sciences, School of Biomedical Sciences, College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, P.O. Box 62000-0202, Nairobi City Square – Kenya
Tel No: +254 711169526, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v6i7.116
